Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and downregulation of NKCC2 protein expression.
about
Hypomagnesemia: a clinical perspective.Drug-induced alterations in Mg2+ homoeostasis.Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients.Serum Magnesium after Kidney Transplantation: A Systematic Review.
P2860
Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and downregulation of NKCC2 protein expression.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Rosiglitazone prevents sirolim ...... n of NKCC2 protein expression.
@en
Rosiglitazone prevents sirolim ...... n of NKCC2 protein expression.
@nl
type
label
Rosiglitazone prevents sirolim ...... n of NKCC2 protein expression.
@en
Rosiglitazone prevents sirolim ...... n of NKCC2 protein expression.
@nl
prefLabel
Rosiglitazone prevents sirolim ...... n of NKCC2 protein expression.
@en
Rosiglitazone prevents sirolim ...... n of NKCC2 protein expression.
@nl
P2093
P2860
P1476
Rosiglitazone prevents sirolim ...... n of NKCC2 protein expression.
@en
P2093
Ana Carolina de Bragança
Antonio Carlos Seguro
Cristianne Alexandre da Silva
Lúcia Andrade
Maria Angela Zanella Fortes
Maria Heloísa Massola Shimizu
Ricardo Rodrigues Giorgi
Talita Rojas Sanches
P2860
P304
P356
10.1152/AJPRENAL.90256.2008
P577
2009-08-05T00:00:00Z